ClinicalTrials.gov record
Not listed Phase 3 Interventional

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation

ClinicalTrials.gov ID: NCT03396068

Public ClinicalTrials.gov record NCT03396068. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 12:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB Study

Study identification

NCT ID
NCT03396068
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 3
Lead sponsor
NeuroRx, Inc.
Industry
Enrollment
72 participants

Conditions and interventions

Interventions

  • Lurasidone HCl Drug
  • NRX-101 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2019
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Last update posted
Jan 18, 2024

2019 – 2024

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
4
Facility City State ZIP Site status
Research Site, Birmingham Birmingham Alabama 35294
Research Centers of America Hollywood Florida 33024
JP Smith Hospital Fort Worth Texas 76104
Research Site, Houston Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03396068, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 18, 2024 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03396068 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →